Vasodilators Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033 | Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc., Eli Lilly and Comp

As per the report, the vasodilators market size has grown strongly in recent years. It will grow from $6.01 billion in 2023 to $6.40 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The vasodilators market size is expected to see strong growth in the next few years. It will grow to $8.22 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=16565&type=smp

Rising Cardiovascular Diseases Propel Vasodilator Market Growth
The rising prevalence of cardiovascular diseases is expected to propel the growth of the vasodilators market going forward. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke, often linked to hypertension and other risk factors. The increasing prevalence of cardiovascular diseases is primarily driven by sedentary lifestyles, poor dietary habits, obesity, tobacco use, and aging populations. Vasodilators are used in cardiovascular diseases to relax blood vessels, reduce blood pressure, and improve blood flow. For instance, in May 2024, according to the Centers for Disease Control and Prevention, a US-based public agency, coronary artery disease (CAD) was responsible for killing 375,476 people in 2021, and about 1 in 20 adults age 20 and older had CAD. Therefore, the rising prevalence of cardiovascular diseases is driving the growth of the vasodilators market.

Sedentary Lifestyles Fuel Growth In The Vasodilator Market

The increased adoption of sedentary lifestyles is expected to propel the growth of the vasodilators market going forward. A sedentary lifestyle refers to limited physical activity and excessive time spent sitting or lying down, often associated with minimal exercise or movement. It is increasing due to modern conveniences such as technology, transportation, and desk-bound jobs, which promote prolonged periods of inactivity. The increased adoption of sedentary lifestyles is driven by technological advancements and modern work environments that prioritize convenience and prolonged sitting. In sedentary lifestyles, vasodilators can improve blood flow and reduce hypertension, mitigating cardiovascular risks. For instance, in September 2023, according to the Centers for Disease Control and Prevention, a US-based national public health agency, new population data from 2022 indicate that 22 states have an adult obesity rate of 35% or higher, up from 19 states in 2021. Therefore, the increased adoption of sedentary lifestyles is driving the growth of the vasodilators market.

Advancements In Soluble Guanylate Cyclase (sGC) Stimulators
Major companies operating in the vasodilators market are focusing on developing advanced products, such as soluble guanylate cyclase (sGC) stimulators, to gain a competitive edge in the market. Soluble guanylate cyclase (sGC) refers to an enzyme found in cells, particularly in smooth muscle cells lining blood vessels. When activated, soluble guanylate cyclase (sGC) converts guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP), leading to vasodilation and increased blood flow. For instance, in September 2022, Bayer AG, a Germany-based pharmaceutical and biotechnology company, launched Vericiguat (Verquvo), a soluble guanylate cyclase (sGC) stimulator for adults with symptomatic chronic heart failure. The drug targets a pathway not currently targeted by existing treatments, reducing the risk of cardiovascular death and hospitalization.

The vasodilators market covered in this report is segmented -

1) By Type: Arterial Dilators, Venous Dilators, Mixed Dilators
2) By Drugs: Nitroglycerin, Alprostadil, Minoxidil, Sorbitrate, Other Drugs
3) By Indication: Hypertension, Angina, Heart Failure, Other Indications
4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
5) By End User: Hospitals, Homecare, Speciality Centres, Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=16565&type=discount

Major companies operating in the vasodilators market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc., Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc. , AstraZeneca, Mayo Foundation for Medical Education and Research (MFMER), Boehringer Ingelheim International GmbH, Bayer AG, Viatris Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen

Contents of the report:
1. Executive Summary
2. Vasodilators Market Report Structure
3. Vasodilators Market Trends And Strategies
4. Vasodilators Market - Macro Economic Scenario
5. Vasodilators Market Size And Growth
…..
27. Vasodilators Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.